ZNF280B
gene geneOn this page
Also known as 5'OY11.1ZNF632
Summary
ZNF280B (zinc finger protein 280B, HGNC:23022) is a protein-coding gene on chromosome 22q11.22, encoding Zinc finger protein 280B (Q86YH2). May function as a transcription factor.
The protein encoded by this gene is a transcription factor that upregulates expression of MDM2, which negatively regulates p53 expression. This gene is highly expressed in prostate cancer cells, which leads to a reduction in p53 levels and an increase in growth of the cancer cells. Several transcript variants have been found for this gene, but only one of them is protein-coding.
Source: NCBI Gene 140883 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 1 total
- MANE Select transcript:
NM_080764
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:23022 |
| Approved symbol | ZNF280B |
| Name | zinc finger protein 280B |
| Location | 22q11.22 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | 5’OY11.1, ZNF632 |
| Ensembl gene | ENSG00000275004 |
| Ensembl biotype | protein_coding |
| Entrez | 140883 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay
ENST00000613655, ENST00000619852, ENST00000626650
RefSeq mRNA: 1 — MANE Select: NM_080764
NM_080764
CCDS: CCDS13799
Canonical transcript exons
ENST00000626650 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003735702 | 22507810 | 22507870 |
| ENSE00003739217 | 22508659 | 22508742 |
| ENSE00003744310 | 22494063 | 22494180 |
| ENSE00003762088 | 22484421 | 22489466 |
Expression profiles
Bgee: expression breadth ubiquitous, 115 present calls, max score 91.79.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.6089 / max 110.6306, expressed in 1035 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 193275 | 3.3051 | 1008 |
| 193274 | 0.2935 | 130 |
| 193276 | 0.0102 | 3 |
Top tissues by expression
122 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 91.79 | gold quality |
| testis | UBERON:0000473 | 82.64 | gold quality |
| right testis | UBERON:0004534 | 81.90 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.47 | gold quality |
| left testis | UBERON:0004533 | 80.99 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 72.90 | gold quality |
| islet of Langerhans | UBERON:0000006 | 72.71 | gold quality |
| primary visual cortex | UBERON:0002436 | 71.41 | gold quality |
| prefrontal cortex | UBERON:0000451 | 70.65 | gold quality |
| hypothalamus | UBERON:0001898 | 70.12 | gold quality |
| ventricular zone | UBERON:0003053 | 69.63 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 69.52 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 69.38 | gold quality |
| cortical plate | UBERON:0005343 | 69.33 | gold quality |
| stromal cell of endometrium | CL:0002255 | 68.73 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 68.31 | gold quality |
| ganglionic eminence | UBERON:0004023 | 68.20 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 68.19 | gold quality |
| cerebral cortex | UBERON:0000956 | 67.91 | gold quality |
| frontal cortex | UBERON:0001870 | 67.78 | gold quality |
| adrenal tissue | UBERON:0018303 | 66.87 | gold quality |
| adrenal gland | UBERON:0002369 | 66.66 | gold quality |
| right adrenal gland | UBERON:0001233 | 66.60 | gold quality |
| left adrenal gland | UBERON:0001234 | 66.60 | gold quality |
| endometrium | UBERON:0001295 | 66.43 | gold quality |
| brain | UBERON:0000955 | 66.11 | gold quality |
| cerebellum | UBERON:0002037 | 65.65 | gold quality |
| cerebellar cortex | UBERON:0002129 | 65.63 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 65.53 | gold quality |
| amygdala | UBERON:0001876 | 65.48 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-9067 | no | 6.19 |
| E-ANND-3 | no | 1.28 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
176 targeting ZNF280B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-6873-3P | 100.00 | 71.42 | 2626 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-4500 | 99.99 | 72.72 | 2367 |
| HSA-LET-7A-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7B-5P | 99.98 | 72.31 | 1790 |
| HSA-LET-7C-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7E-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7F-5P | 99.98 | 72.56 | 1784 |
| HSA-LET-7G-5P | 99.98 | 72.37 | 1784 |
| HSA-LET-7I-5P | 99.98 | 72.37 | 1788 |
| HSA-MIR-98-5P | 99.98 | 72.33 | 1787 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-3173-3P | 99.98 | 66.49 | 1217 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-LET-7D-5P | 99.96 | 71.76 | 1632 |
| HSA-MIR-4458 | 99.96 | 71.64 | 1650 |
Literature-anchored findings (GeneRIF, showing 1)
- ZNF280B upregulates GUCY1A3 expression and downregulates TP53 in prostate cancer cells. (PMID:24236047)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Zfp280b | ENSMUSG00000049764 |
| rattus_norvegicus | Zfp280b | ENSRNOG00000028441 |
Paralogs (28): ZNF280C (ENSG00000056277), ZBTB25 (ENSG00000089775), PRDM13 (ENSG00000112238), BCL6 (ENSG00000113916), FEZF1 (ENSG00000128610), ZBTB46 (ENSG00000130584), PRDM12 (ENSG00000130711), ZNF280D (ENSG00000137871), NACC2 (ENSG00000148411), FEZF2 (ENSG00000153266), ZBTB7B (ENSG00000160685), NACC1 (ENSG00000160877), BCL6B (ENSG00000161940), GFI1 (ENSG00000162676), GFI1B (ENSG00000165702), ZBTB49 (ENSG00000168826), ZNF280A (ENSG00000169548), ZNF581 (ENSG00000171425), ZNF524 (ENSG00000171443), ZBTB26 (ENSG00000171448), ZBTB21 (ENSG00000173276), ZNF683 (ENSG00000176083), ZBTB33 (ENSG00000177485), ZBTB3 (ENSG00000185670), ZBTB6 (ENSG00000186130), ZBTB14 (ENSG00000198081), ZBTB12 (ENSG00000204366), ZNF580 (ENSG00000213015)
Protein
Protein identifiers
Zinc finger protein 280B — Q86YH2 (reviewed: Q86YH2)
Alternative names: 5’OY11.1, Suppressor of hairy wing homolog 2, Zinc finger protein 279, Zinc finger protein 632
All UniProt accessions (2): Q86YH2, A0A0D9SEJ8
UniProt curated annotations — full annotation on UniProt →
Function. May function as a transcription factor.
Subcellular location. Nucleus.
RefSeq proteins (1): NP_542942* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR013087 | Znf_C2H2_type | Domain |
| IPR025243 | DUF4195 | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050527 |
Pfam: PF13836
UniProt features (19 total): zinc finger region 4, compositionally biased region 3, modified residue 3, cross-link 3, region of interest 3, sequence variant 2, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q86YH2-F1 | 59.83 | 0.26 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (6): 1, 68, 70, 173, 247, 261
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 118 (showing top):
TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, SENESE_HDAC3_TARGETS_DN, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, DELACROIX_RAR_BOUND_ES, JNK_DN.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, GSE10240_CTRL_VS_IL17_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_DN, CBX5_TARGET_GENES, HOXD11_TARGET_GENES, MIER1_TARGET_GENES, NAB2_TARGET_GENES, SFMBT1_TARGET_GENES, SNRNP70_TARGET_GENES, ZBTB12_TARGET_GENES
GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)
GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 2 |
| DNA-templated transcription | 1 |
| regulation of gene expression | 1 |
| regulation of RNA biosynthetic process | 1 |
| regulation of DNA-templated transcription | 1 |
| transcription by RNA polymerase II | 1 |
| cis-regulatory region sequence-specific DNA binding | 1 |
| chromatin | 1 |
| DNA-binding transcription factor activity | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| transition metal ion binding | 1 |
| nucleic acid binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
592 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZNF280B | PRAME | P78395 | 645 |
| ZNF280B | GGTLC2 | Q14390 | 600 |
| ZNF280B | POM121L1P | Q3SYA9 | 581 |
| ZNF280B | HSFY1 | Q96LI6 | 578 |
| ZNF280B | TSPY1 | P09002 | 506 |
| ZNF280B | ZNF425 | Q6IV72 | 474 |
| ZNF280B | CDYL | Q9Y232 | 459 |
| ZNF280B | A6NGT6 | A6NGT6 | 447 |
| ZNF280B | SETD4 | Q9NVD3 | 443 |
| ZNF280B | DYNC1LI1 | Q9Y6G9 | 433 |
| ZNF280B | FBXO16 | Q8IX29 | 432 |
| ZNF280B | RPL23A | P29316 | 418 |
| ZNF280B | A0A1W2PQ80 | A0A1W2PQ80 | 403 |
| ZNF280B | IGKV2D-29 | A0A075B6S2 | 401 |
| ZNF280B | A0A087WY85 | A0A087WY85 | 393 |
| ZNF280B | CCDC71L | Q8N9Z2 | 393 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ZNF280A | NUCB2 | psi-mi:“MI:0914”(association) | 0.350 |
| ZMYM2 | ZBTB5 | psi-mi:“MI:2364”(proximity) | 0.270 |
BioGRID (7): ZNF280B (Affinity Capture-MS), ZNF280B (Proximity Label-MS), ZNF280B (Proximity Label-MS), ZNF280B (Affinity Capture-MS), ZNF280B (Affinity Capture-RNA), ZNF280B (Affinity Capture-RNA), ZNF280B (Two-hybrid)
ESM2 similar proteins: A0A0R4IYX6, A0A1D5NVS8, A0AVK6, A7MBJ2, A9JRX0, B7ZS37, B8A5Y1, D3ZF42, E1BE02, E1BKK0, E1BLP6, F1LMN3, F1QLG5, F6NSX9, F6YVB9, P59817, Q01954, Q0VEE6, Q2TB10, Q2YDE2, Q3U1C4, Q4R7L6, Q56NI9, Q58FA4, Q5T0L3, Q5ZIX8, Q5ZJ69, Q61464, Q63679, Q68FE8, Q6IQ32, Q6P1H6, Q6P3Y5, Q6PCM1, Q6S7F2, Q70YC5, Q7Z3K3, Q7Z4V0, Q7ZZ00, Q86YH2
Diamond homologs: P59817, Q5PPG4, Q68FE8, Q6N043, Q6P3Y5, Q7Z3K3, Q86YH2, Q8BZH4, Q8ND82, Q99KZ6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
1 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
734 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 22:22494069:T:TA | donor_gain | 1.0000 |
| 22:22508654:CTT:C | donor_loss | 0.9900 |
| 22:22508655:TTA:T | donor_loss | 0.9900 |
| 22:22508656:TACCA:T | donor_loss | 0.9900 |
| 22:22508657:A:AG | donor_loss | 0.9900 |
| 22:22508658:CCAGT:C | donor_gain | 0.9900 |
| 22:22508657:A:AC | donor_gain | 0.9800 |
| 22:22508658:C:CC | donor_gain | 0.9800 |
| 22:22507882:C:CT | acceptor_gain | 0.9700 |
| 22:22491976:A:C | acceptor_gain | 0.9500 |
| 22:22494058:CAGA:C | donor_loss | 0.9500 |
| 22:22494059:AGAC:A | donor_loss | 0.9500 |
| 22:22494060:GAC:G | donor_loss | 0.9500 |
| 22:22494061:A:AT | donor_loss | 0.9500 |
| 22:22494062:CC:C | donor_loss | 0.9500 |
| 22:22494063:C:G | donor_loss | 0.9500 |
| 22:22508652:T:TA | donor_gain | 0.9500 |
| 22:22487794:TTTAG:T | donor_gain | 0.9400 |
| 22:22494180:CCT:C | acceptor_loss | 0.9200 |
| 22:22494182:T:C | acceptor_loss | 0.9200 |
| 22:22489467:CTA:C | acceptor_loss | 0.9100 |
| 22:22489468:T:G | acceptor_loss | 0.9100 |
| 22:22494176:CCAGC:C | acceptor_gain | 0.9100 |
| 22:22494177:CAGC:C | acceptor_gain | 0.9100 |
| 22:22494177:CAGCC:C | acceptor_gain | 0.9100 |
| 22:22506459:G:T | donor_gain | 0.9100 |
| 22:22506489:TGGTG:T | donor_gain | 0.9100 |
| 22:22494054:A:AC | donor_gain | 0.9000 |
| 22:22494181:C:CC | acceptor_gain | 0.8900 |
| 22:22508511:C:A | donor_gain | 0.8800 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000189032 (22:22498411 A>C), RS1000208161 (22:22492059 T>C), RS1000237709 (22:22500713 G>T), RS1000237927 (22:22492404 G>A,C), RS1000363589 (22:22504276 A>G), RS1000469568 (22:22485377 A>C), RS1000540922 (22:22490593 G>C), RS1000543791 (22:22486359 A>C,T), RS1000622835 (22:22501279 G>A), RS1000780303 (22:22493946 C>T), RS1000870646 (22:22506441 C>T), RS1001242288 (22:22499304 G>C), RS1001473694 (22:22505224 G>C), RS1001542032 (22:22484645 G>A,C,T), RS1001590697 (22:22505469 G>A,C)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
31 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | decreases expression, decreases methylation, affects cotreatment | 6 |
| sodium arsenite | affects cotreatment, increases abundance, increases expression | 2 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| FR900359 | increases phosphorylation | 1 |
| TAK-243 | increases sumoylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| trichostatin A | decreases expression | 1 |
| manganese chloride | affects cotreatment, increases abundance, increases expression | 1 |
| potassium chromate(VI) | decreases expression | 1 |
| nickel sulfate | increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| pentabromodiphenyl ether | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | decreases expression, affects cotreatment | 1 |
| dorsomorphin | affects cotreatment, decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Caffeine | increases phosphorylation | 1 |
| Formaldehyde | decreases expression | 1 |
| Lead | affects methylation | 1 |
| Manganese | affects cotreatment, increases abundance, increases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Vanadates | increases expression | 1 |
| Antirheumatic Agents | decreases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Cellosaurus cell lines
3 cell lines: 3 embryonic stem cell
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_A8G2 | SEES3-1V human ZNF280B, clone1 | Embryonic stem cell | Male |
| CVCL_A8G3 | SEES3-1V human ZNF280B, clone2 | Embryonic stem cell | Male |
| CVCL_A8G4 | SEES3-1V human ZNF280B, clone3 | Embryonic stem cell | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.